OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Clinical burden of hemophilia in older adults: Beyond bleeding risk	143
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	94
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	62
Editorial Board	58
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	57
Radiation and leukaemia: Which leukaemias and what doses?	56
Advances in the critical care management for patients with hematological malignancies	56
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	56
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	53
Not all LGL leukemias are created equal	53
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	50
Artificial intelligence in sickle disease	50
Thalassaemia in China	49
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	47
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	43
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	41
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	41
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	41
Chasing leukemia differentiation through induction therapy, relapse and transplantation	40
Adenovirus infection in adult allogeneic hematopoietic stem cell transplant recipients: Systematic review and meta-analysis	40
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	39
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	38
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	37
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	34
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia	34

Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	33
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	32
Endothelial cells: major players in acute myeloid leukaemia	31
Old tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults	30
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	30
Preservation of fertility in female patients with hematologic diseases	30
CHIPing away the progression potential of CHIP: A new reality in the making	29
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	29
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	27
Current challenges in conditioning regimens for MDS transplantation	25
Richter's transformation: Transforming the clinical landscape	25
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	25
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review	24
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	24
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies	24
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	23
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	23
Down syndrome and leukemia: An insight into the disease biology and current treatment options	23
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	23
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	22
Optimizing high dose melphalan	22
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	22
The mythological chimera and new era of relapse prediction post-transplant	21
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists	20
Complementary and alternative medicine for children with sickle cell disease: A systematic review	20
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	20
Current state and next-generation CAR-T cells in multiple myeloma	20
Beyond the blood: A practical guide to thalassemia care in the emergency department	19
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	19
Αlpha-thalassemia: A practical overview	19
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	19
Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity	18
Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms	18
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	18
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	17
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	17
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	17
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	17
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	17
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	17
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	16
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies	16
Innovations in red blood cell preservation	16
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	16
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	16
The use of bone-modifying agents in multiple myeloma	16
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	16
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	16